SCHEMBL17697115

SCHEMBL17697115

c1cn2ccnc2c(N2CCC3(CCNCC3)C2)n1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.48
CYP3A4 P08684 5/20 0.48
TSHR P16473 5/20 0.48
ALDH1A1 P00352 7/20 0.47
HSD17B10 Q99714 6/20 0.47
CYP1A2 P05177 4/20 0.47
AKT1 P31749 1/20 0.46
CYP2C9 P11712 3/20 0.46
CYP2C19 P33261 3/20 0.46
HPGD P15428 3/20 0.45
HTR2C P28335 1/20 0.44
USP2 O75604 2/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
CDC42BPB Q9Y5S2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5496661 0.78 HTR2C (0.65) HTR2C
Hydrochloric Acid SCHEMBL11172195 0.75 HTR2C (0.61) HTR2C
SCHEMBL17687760 0.73 CYP11B2 (0.46) CYP3A4ALDH1A1CYP2C19
Hydrochloric Acid SCHEMBL30329706 0.72 CYP2D6 (0.46) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL939303 0.71 CYP3A4 (0.82) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL15760261 0.70 ACKR3 (0.35) AKT1
Hydrochloric Acid SCHEMBL484648 0.70 CYP3A4 (0.80) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL7008715 0.70 CYP3A4 (0.80) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL20021215 0.69 HTR2C (0.45) TSHRALDH1A1HTR2C
SCHEMBL22941348 0.68 ALDH1A1 (0.55) CYP2D6CYP3A4TSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170275302-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. 2017-09-28 US disclosed
US-20170275302-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. 2017-09-28 US disclosed
WO-2016060941-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2016-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275302-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 CYP2D6 3056/4885CYP3A4 4370/4885TSHR 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.